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Abstract A liquid chromatography–tandem mass spec-
trometry method for the analysis of seven antiviral drugs,
zanamivir, ribavirin, oseltamivir, oseltamivir carboxylate,
amantadine, rimantadine and arbidol, in poultry muscle is
reported. The antiviral drugs were extracted from the
homogenized poultry muscle sample using methanol.
The extract was purified using tandem solid-phase extraction
combining a cation exchange cartridge and a phenyl-
boronic acid cartridge. To prevent excessive matrix
effects, the analytes were separated from the matrix
constituents using a column-switch liquid chromatogra-
phy system combining a reversed-phase and a Hyper-
carb analytical column. Detection was carried out using
tandem mass spectrometry. The method was fully validated
according to 2002/657/EC [1] and proved to be adequate for
quantification and confirmation of zanamivir and ribavirin at
10 μg kg−1, oseltamivir, oseltamivir carboxylate, amantadine
and rimantadine at levels below 1.0 μg kg−1 and for qualita-
tive confirmatory analysis of arbidol at levels below
1 μg kg−1.
Keywords Antiviral drugs .Mass spectrometry . Poultry
muscle . Residue analysis
Introduction
Influenza infections continue to pose a serious problem.
Recent outbreaks of avian influenza (H5N1) have had a
huge economic effect in the poultry breeding sector [2, 3]
but besides the economic effect, human health is at stake
because avian influenza can also infect mammals including
humans [4, 5]. The increasing incidence of resistance to
antiviral drugs is a major concern to public health. Because
strains tend to become more aggressive, adequate therapeu-
tic strategies are needed [6].
Progress has been made by identifying several com-
pounds that aid in the treatment of viral infections and
besides the treatment of humans, these are used by farmers
to protect their flocks [7]. However, concerns arose about
the increasing incidence of resistance to antiviral drugs [7–
12]. Several causes have been suggested including the inap-
propriate use of antiviral drugs in the treatment of humans
during the outbreaks of avian influenza and severe acute
respiratory syndrome (SARS) [13, 14]. Furthermore, it has
been shown that oseltamivir carboxylate (Fig. 1) is not
removed or degraded in normal sewage water treatment
and thus enters the environment [15]. Waterfowl are then
in a position to ingest the active oseltamivir carboxylate.
This could drive the selection of resistant avian influenza A
strains in the gut. Especially in countries (e.g. Southeast
Asia) where waterfowl and humans come in close contact,
this could lead to the spread of other strains incorporating
the resistance genes and change of host [16, 17]. Finally,
amantadine, oseltamivir and arbidol (Fig. 1) are allegedly
being administered to poultry and other livestock in China,
Southeast Asia and Russia [7, 18, 19]. To prevent excessive
use of antiviral drugs the Food and Drug Administration
(FDA) prohibited the non-consistent use of two types of
antiviral drugs in chickens, turkeys and ducks: the
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amantadines, including amantadine and rimantadine, and the
neuramidase inhibitors, including zanamivir and oseltamivir
(Fig. 1) [20].
To be able to detect extra-label use of antiviral drugs,
analytical methods are needed that not only detect the pres-
ence of antiviral drugs in poultry muscle, but are also able to
quantify the concentration present and to confirm the iden-
tity of the compound present at levels as low as reasonably
possible. Single-residue methods for the quantitative analy-
sis of antiviral drugs in biological matrices using mass
spectrometry have been published for zanamivir [21, 22],
ribavirin [23–26], oseltamivir [17, 27–30] (some of them
including oseltamivir carboxylate [27, 30]), oseltamivir car-
boxylate only [31], amandatine [32–34], some of them
including rimantadine [33, 35, 36], and arbidol [37, 38].
Recently, Chan et al. [39] reported a multi-compound meth-
od for the analysis of antiviral drugs in poultry muscle using
zwitterionic hydrophilic interaction liquid chromatography
(zic-HILIC) in combination with mass spectrometric detec-
tion. However, this method is suitable for screening purpo-
ses only and it is limited to the analysis of basic and
amphoteric antiviral drugs.
For efficient control of antiviral drug usage, a quantita-
tive confirmatory multi-method is needed that is adequate
for analysis of the antiviral drugs that are applied in poultry
breeding including zanamivir, ribavirin, oseltamivir includ-
ing its active metabolite oseltamivir carboxylate, amanta-
dine, rimantadine and arbidol. The main difficulty in the
development of a multi-method for the analysis of antiviral
drugs is their broad range of physical and chemical properties.
The antiviral drugs include the extremely polar zanamivir and
ribavirin, whereas arbidol is reasonably non-polar. Further-
more, the selection includes basic, amphoteric and neutral
drugs.
This paper presents a tandem solid-phase extraction
clean-up in combination with a column-switch liquid chro-
matography (LC) system for the quantitative confirmatory
analysis of a broad range of antiviral drugs in poultry
muscle. The necessity of using tandem SPE and two analyt-
ical columns to adequately remove matrix effects and thus to
enable quantitative analysis of the antiviral drugs is demon-
strated. The method was fully validated for zanamivir, riba-
virin, oseltamivir, oseltamivir carboxylate, amantadine,
rimantadine and arbidol. This is the first time a quantitative
confirmatory method for the analysis of a broad range of
antiviral compounds is presented.
Experimental
Reagents and equipment
HPLC grade methanol (MeOH) and acetonitrile (ACN) were
obtained from Biosolve (Valkenswaard, the Netherlands).
Formic acid (FA) and ammonia (25% solution in water) were
obtained from Merck (Darmstadt, Germany). Milli-Q water
was prepared using a Milli-Q system at a resistivity of at least
18.2MΩ cm−1 (Millipore, Billerica, MA, USA). Rimantadine
HCl (99% purity) and amantadine HCl (100% purity) were
obtained from Sigma-Aldrich (St. Louis, MO, USA) and
arbidol (99.3% purity) from Amplachem (Carmel, IN,
USA). Zanamivir (100% purity), ribavirin (99.5% purity),
Fig. 1 Chemical structures of (a) zanamivir, (b) ribavirin, (c) oseltamivir, (d) oseltamivir carboxylate, (e) rimantadine, (f) amantadine and (g) arbidol
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oseltamivir phosphate (98% purity) and oseltamivir car-
boxylate (98% purity), and the internal standards
zanamivir-13C15N2, ribavirin-
13C5, oseltamivir-d3 phosphate,
oseltamivir-d3 carboxylate, rimantadine-d4 HCl and
amantadine-d15 HCl were obtained from Toronto Research
Chemicals (North York, ON, Canada). Stock solutions of
oseltamivir, amantadine, rimantadine, their corresponding iso-
topically labelled internal standards and arbidol were prepared
at 100 mg L−1 in MeOH. Stock solutions of zanamivir, riba-
virin, oseltamivir carboxylate and their isotopically labelled
internal standards were prepared at 100 mg L−1 in water. All
dilutions of the stock solutions were prepared fresh daily in
Milli-Q water.
Sample preparation
One gram of a poultry tissue was transferred into a polypro-
pylene (PP) centrifuge tube and 4 mL of MeOH was added
while shaking using a vortex mixer. Subsequently, the tube
was shaken for 15 min on a rotary tumbler. After centrifu-
gation (3,600 g, 15 min), the upper layer was isolated by
decanting it into a PP centrifuge tube and acidified by add-
ing 20 μL of FA prior to the tandem solid-phase extraction
(SPE) procedure (Fig. 2a).
A Phenomenex (Torrance, CA, USA) Strata-X C
200 mg/6 mL strong cation exchange SPE cartridge was
conditioned with 4 mL 0.5 v/v % FA inMeOH, pH 2. A clean
PP centrifuge tube was placed under the Strata-X C cartridge
before the acidified sample extract, followed by 1 mL of
MeOH, pH 2, was applied onto the cartridge. The total break-
through was collected in the PP centrifuge tube (fraction A).
After addition of 200 μL of 25% ammonia, fraction A was
centrifuged (3,600 g, 15 min) and set aside. The Strata-X C
cartridge was washed with 4 mL of MeOH, pH 2. A clean PP
centrifuge tube was placed under the SPE cartridge and the
antiviral compounds were eluted from the cartridge using
4 mL 0.75 v/v % ammonia in MeOH, pH 12, which was
collected in the PP centrifuge tube (fraction B). An Agilent
Technologies (Santa Clara, CA, USA) Bond elute phenylbor-
onic acid (PBA) 100 mg/3 mL SPE cartridge was conditioned
with 2 mL 0.5 v/v % FA in H2O, pH 2, followed by 4 mL
MeOH, pH 12. The basified fraction A was applied onto the
PBA cartridge, which was subsequently washed with 4 mL
MeOH, pH 12. The PP centrifuge tube containing fraction B
was placed under the PBA cartridge and ribavirin was eluted
from the cartridge using 4 mL MeOH, pH 2, which was
combined with fraction B. The solvent of the combined frac-
tions was evaporated under a gentle nitrogen stream at 50 °C
until dry. The residue was redissolved in 250 μL water and
transferred into a liquid chromatography–tandem mass spec-
trometry (LC–MS/MS) autosampler vial.
LC–MS/MS analysis
A schematic presentation of the column-switch system is
presented in the Electronic Supplementary Material Fig. S1.
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Fig. 2 Schematic representation of (a) the dual SPE procedure and (b) the LC procedure. Z zanamivir, RB ribavirin, O oseltamivir, OC oseltamivir
carboxylate, AM amantadine, RM rimantadine, AB arbidol
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‘LC 1’ consisted of an Acquity vacuum degasser, autosam-
pler and binary solvent pump (Waters, Milford, MA, USA).
‘LC 2’ consisted of a Separations (Hendrik-Ido-Ambacht,
the Netherlands) vacuum degasser, mixing chamber and two
type K-1001 HPLC pumps. ‘V1’ and ‘V2’ are 6-way valves
(Separations), which are operated by ‘LC 1’. ‘MS’ is a mass
spectrometer Quattro Premier XE (Waters, Milford, MA,
USA). ‘Column1’ is a Waters Symmetry C18 (3.0×150 mm,
5 μm) analytical column and ‘column 2’ is a Thermo Fisher
Scientific (Waltham MA, USA) Hypercarb (3.0×100 mm,
5 μm) analytical column.
From the initial time ‘LC 1’ runs a gradient (solvent A,
50 mM FA in water; solvent B, 50 mM FA in ACN): 0–
6.0 min, linear increase from 0% to 5% B; 6.0–14.0 min,
linear increase to 100% B; 14.0–14.5 min, linear decrease to
0% B; 14.5–20.0 min, equilibration at 0% B, operating at a
flow of 0.4 mL min−1. ‘LC 2’ runs a gradient using the same
solvents: 0–6.0 min, 5% B; 6.0–10.0 min, linear increase to
100% B; 10.0–11.0 min, 100% B; 11.0 – 12.0 min, linear
decrease to 0% B; 12.0–20.0 min, equillibration at 0% B,
operating at a flow of 0.4 mL min−1. The injection volume
(injected at ‘LC 1’) is 50 μL.
During phase 1, running from the initial time until 6 min,
both columns are placed in series. At the start of phase 2
(6.0 min) ‘V2’ is switched and the mobile phase of ‘LC 1’
runs solely through the Symmetry C18 column and is
diverted to waste, whereas the mobile phase of ‘LC 2’ runs
through the Hypercarb column and enters the MS. At the
start of phase 3 (10.0 min) ‘V1’ is switched and the mobile
phase of ‘LC 1’ runs solely through the Symmetry C18
column and enters the MS, whereas the mobile phase run-
ning through the Hypercarb column is diverted to waste.
Detection was carried out using the mass spectrometer in
positive electrospray ionization (ESI) mode. The operating
parameters were capillary voltage, 1.0 kV; source offset,
50 V; cone voltage, Table 1; source temperature, 150 °C;
desolvation temperature, 450 °C; cone gas flow, 100 L h−1;
and desolvation gas, 600 L h−1. The antiviral compounds
were fragmented using collision-induced dissociation and
the selected reaction monitoring (SRM) transitions are given
in Table 1. Data were acquired and processed usingMassLynx
4.1 software (Waters). Zanamivir-13C15N2, ribavirin-
13C5,
oseltamivir-d3, oseltamivir carboxylate-d3, amantadine-d15
and rimantadine-d4 were used as the internal standards. No
internal standard for arbidol was available.
Method optimisation
During method development recovery and matrix effects
were monitored. Recovery was calculated by dividing the
signal of a blank poultry sample with addition of the com-
pounds before sample clean-up (matrix-matched standard,
MMS) by the signal of a blank poultry muscle sample with
addition of an equivalent amount of the compounds, based
upon 100% recovery, after sample clean-up (matrix-
matched recovery standard, MMRS). The matrix effect
Table 1 Retention time, cone
voltage, SRM transitions and
measurement time of the
antiviral compounds and their
internal standards
aMost abundant product ion
Compound Retention
time (min)
Cone Voltage
(V)
Precursor
Ion (m/z)
Product
ion (m/z)
Collision
energy (eV)
Measurement
time (min)
Zanamivir 8.5 25 333.0 60.1a 15 0-10
120.9 25
Zanamivir-13C15N2 8.5 25 336.0 63.1 15 0–10
Ribavirin 9.5 12 245.0 96.0a 25 0–10
113.0 15
Ribavirin-13C5 9.5 12 250.1 113.0 15 0–10
Oseltamivir 11.5 15 313.2 166.0a 20 10–12.1
225.1 10
Oseltamivir-d3 11.5 15 316.2 167.0 20 10–12.1
Oseltamivir
carboxylate
11.1 15 285.20 137.9a 20 10–12.1
197.1a 10
Oseltamivir
carboxylate-d3
11.1 15 288.2 200.1a 10 10–12.1
Rimantadine 11.5 25 180.1 80.8a 25 10–12.1
163.1 15
Rimantadine-d4 11.5 25 184.1 167.1 15 10–12.1
Amantadine 11.0 25 152.1 93.0a 30 10–12.1
135.0 18
Amantadine-d15 11.0 25 167.30 150.1 15 10–12.1
Arbidol 12.9 25 477.10 279.0a 30 11.8–20
432.0 18
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was calculated by dividing the signal of the MMRS by the
signal of a standard solution in water at equivalent concen-
tration. No matrix effects are present if the result of this
calculation is 100%. If the result is below 100%, suppression
occurs and if the result is above 100%, signal enhancement
occurs.
As an alternative to the column-switch set-up, different
single analytical columns were tested. zic-HILIC (Sequant,
Umeå, Sweden) was tested in combination with gradient
elution using ammonium formate in water and ACN or
MeOH as the mobile phase, at a pH ranging from 3 to 10.
Reversed-phase (RP) C18 was tested in combination with
gradient elution using water and ACN or MeOH as the
mobile phase, at a pH ranging from 3 to 11. Hypercarb
was tested in combination with gradient elution using water
and ACN, MeOH or tetrahydrofuran as the mobile phase.
For each chromatographic condition, the matrix effects were
evaluated on the basis of spiked poultry muscle samples
using only a methanolic extraction in combination with
evaporation of the extraction solvent and redissolution in a
suitable solvent. We aimed for a chromatographic system
that results in sufficient retention for all compounds and
adequate separation of the antiviral drugs from the matrix
constituents to minimize matrix effects.
SPE using strong cation exchange and PBA were tested
for sample clean-up. A 50 μg kg−1 spiked methanolic sample
extract was acidified and applied onto a Strata-X C cartridge.
The breakthrough during application and washing were col-
lected separately. These and the eluent were analysed using
the LC–MS/MS system. The same procedure was followed
for the PBA cartridges, but then the spiked methanolic extract
was basified prior to application.
Method validation
A full validation was carried out according to 2002/657/EC
[1]. The following parameters were determined: linearity,
trueness, repeatability, within-laboratory reproducibility,
decision limit (CCα), detection capability (CCβ), selectivity
and robustness. The validation was carried out on three
different occasions, by two different technicians, using different
batches of SPE cartridges and including 21 different poultry
muscle samples.
Linearity
On three different days a matrix-matched calibration line
was prepared including the following calibration levels: 0,
2.5, 5, 10, 15 and 20 μg kg−1 (six data points including zero)
by adding solutions of the antiviral drugs to blank poultry
muscle samples. Calibration lines were constructed by plot-
ting the peak areas normalized by the peak areas of the
internal standards, versus the added concentration and
carrying out least-squares linear regression. The linearity
was considered acceptable if the coefficient of correlation
was at least 0.990.
Trueness, repeatability and within-lab reproducibility
On each of the 3 days seven different blank poultry muscle
samples were selected and analysed as such and spiked at 5,
10 and 15 μg kg−1. For each sample the level of the indi-
vidual antiviral drugs was calculated using the calibration
line constructed on the same day. The trueness was calcu-
lated for each level by dividing the overall average calcu-
lated concentration by the nominal concentration.
According to 2002/657/EC [1] the trueness at the selected
validation levels should be between 80 and 110%.
The repeatability and within-lab reproducibility were
calculated using single factor analysis of variance
(ANOVA). According to 2002/657/EC [1] the relative
within-laboratory reproducibility (RSDRL) and relative
repeatability (RSDr) are considered acceptable if they
are below the value calculated from the Horwitz equation
[40] and two thirds of that value, respectively (i.e. below
31.7% and 21.1%, respectively, at a validation level of
10 μg kg−1). Thompson [41], however, demonstrated that
the Horwitz equation is not applicable to the lower
concentration range (<120 μg kg−1) and suggested a
complementary model. On the basis of this model the
RSDRL and RSDr are acceptable if they are below 22%
and 14.7%, respectively. The latter, more stringent crite-
ria were adopted for this validation study. It is stated that
because different poultry muscle samples were used
within 1 day, the repeatability is not the pure repeatabil-
ity as stated in 2002/657/EC [1]. However, using differ-
ent poultry muscle samples within 1 day provides a
better understanding of the between-sample variation
and the validation better reflects a routine analysis
situation.
Decision limit and detection capability
Within the EU no regulations for the use of antiviral
drugs in food production are established. Within the
USA, the FDA prohibited extra-label use of antiviral
drugs [20]. Therefore, confirmation of the identity of
antiviral drugs should be carried out at levels as low as
reasonably possible. Therefore, the decision limit (CCα)
was calculated on the basis of zero tolerance in accor-
dance with 2002/657/EC [1] to assign samples that con-
tain antiviral drugs and thus deviate from the blank
population (α-error is 1%). CCα was calculated on the
basis of the bandwidth of the signal in blank samples
(n021) in the time window in which the analyte is
expected. CCβ is the detection capability and expresses
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the concentration of the antiviral drugs in a poultry muscle at
which the sample will be found non-compliant (β-error is
5%). CCβ was determined on the basis of the bandwidth of
the signal in blank samples (n021) and the bandwidth of the
signal in the samples spiked at 10 μg kg−1 (zanamivir and
ribavirin, n021) or 5 μg kg−1 (other antiviral drugs, n021) in
the time window in which the analyte is expected. The indi-
vidual blank and spiked samples were analysed on three
different occasions and calculations were carried out as sug-
gested by Antignac et al. [42], but without a normalisation
based on the signal of the internal standards.
Selectivity
The selectivity of the method was studied on the basis
of a practical and a theoretical study. Firstly, the 21
analysed blank samples were checked for interferences
at the retention times corresponding to the antiviral
drugs. Secondly, databases were searched for com-
pounds having a molecular mass equal to the antiviral
drugs that could possibly be present in poultry muscle
samples. Standard solutions of 100 μg L−1 of androsta-
1,4-diene-3,17-dione (ADD), 5-hydroxyflunixin and tet-
rahydrogestrinone (THG), indicated as possibly interfer-
ing compounds, were analysed using the developed
method. The resulting chromatograms were checked for
interferences at the retention times corresponding to the
antiviral drugs.
Robustness
The robustness of the method became clear during the
optimisation of the sample preparation, chromatographic
conditions and MS parameters. Additionally, some minor
changes to the method were tested in duplicate: (1) extrac-
tion for 30 min instead of 15, (2) dry the PBA cartridges by
applying vacuum for 1 min after applying the extract and
after washing the cartridge and (3) evaporation of the sol-
vent at 55 °C instead of 50 °C. The trueness and repeatabil-
ity of the results were compared to the characteristics of the
regular method.
Application to real samples
The suitability of the developed method was tested by
applying it to affected sample materials. Amantadine-
affected poultry and turkey muscle were a kind gift from
the Food and Environmental Research Agency (FERA),
York, UK. The determined levels using the developed
method were compared to the indicated amantadine con-
centration in the samples, being approximately 4 μg kg−1
for the poultry muscle and 8–25 μg kg−1 for the turkey
muscle.
Results and discussion
Chromatography
Stationary phases using three different interaction mecha-
nisms were tested to obtain sufficient separation power and
separate the antiviral drugs from matrix constituents. There-
fore, a retention factor of at least 2 should be obtained. The
use of zic-HILIC was reported by Chan et al. [39] for the
screening analysis of some antiviral drugs. However, using
zic-HILIC no retention was obtained for arbidol, the most
non-polar compound we studied and which was not includ-
ed in the screening method reported by Chan et al. [39].
Only slight improvement in the retention time (RT) was
made by protonating arbidol (pKa 6) using a mobile phase
of pH≤4 and lowering the ammonium formate concentra-
tion to 5 mM. Nevertheless, insufficient retention was
obtained for arbidol and severe matrix effects, even for
late-eluting polar compounds like zanamivir and ribavirin,
were observed (Fig. 3).
Using RP chromatography applying C18 columns, zana-
mivir eluted at the dead time of the system and only slight
retention was obtained for ribavirin (retention factor of 0.4).
Although the matrix effects significantly decreased for riba-
virin, zanamivir was completely suppressed by matrix con-
stituents (Fig. 3) and was therefore not detectable, even at a
concentration of 50 μg kg−1 in poultry muscle.
When using Hypercarb as the stationary phase, all
antiviral drugs, including the most polar compounds
zanamivir and ribavirin obtained retention (retention fac-
tor of 3.0 and 4.6 respectively). The matrix suppression
for zanamivir decreased from 100% using zic-HILIC or C18 to
97% (Fig. 3) resulting in the detection of zanamivir in
poultry muscle at a concentration of 50 μg kg−1. For
ribavirin, instead of signal suppression, signal enhancement
was observed (signal MMRS/signal standard 255%). The
main disadvantage of the use of a Hypercarb column is that
arbidol, the most non-polar compound studied, does not
elute from the column. It contains a free phenyl group,
which strongly interacts with the column material, prevent-
ing its elution even when using tetrahydrofuran as the
mobile phase.
To be able to analyse the antiviral drugs within one run, a
column-switch system combining a C18 column with a
Hypercarb column was developed. A schematic of the LC
procedure is given in Fig. 2b. Zanamivir and ribavirin are
not or hardly retained by the C18 column, elute from it
within 5 min and are subsequently retained on the Hyper-
carb column. After that, on the Hypercarb column, zanami-
vir and ribavirin are separated from the matrix constituents
using a gradient and are directly detected by MS. In the
meantime the other antiviral compounds are retained on the
C18 column. After elution of zanamivir and ribavirin from
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the Hypercarb column, the other antiviral drugs are eluted
from the C18 column by increasing the organic content of
the mobile phase, passing by the Hypercarb column and
entering the MS directly. The total run time, including
equilibration of both columns, is 20 min. As presented in
Fig. 3, the matrix effects using the column-switch LC sys-
tem are tremendously improved for zanamivir.
Sample clean-up
To further reduce the matrix effects and therefore to facili-
tate detection and confirmation at a concentration of at least
10 μg kg−1 in poultry muscle, additional sample clean-up
proved to be necessary. Two different SPE systems were
tested: Strata-X C and PBA. The relative amounts of the
antiviral drugs in the breakthrough during application of the
sample extract on the cartridge, the breakthrough during
washing and the eluent are presented in Fig. 4a, b.
Because ribavirin remains neutral at pH 2, it does not
interact with the Strata-X C cartridge and elutes during
application of the extract and the washing procedure. The
other antiviral compounds are positively charged at pH 2
and therefore are retained. Only zanamivir, having the low-
est pKa of all the antiviral compounds (pKa 3.8), shows 10%
breakthrough during the washing procedure which is con-
sidered acceptable. The Strata-X C cartridge is considered
suitable for the clean-up of all antiviral drugs included
except for ribavirin.
The PBA material has multiple interaction mechanisms.
The strongest is the covalent binding at high pH with cis-
diol groups, as present in ribavirin. Other mechanisms in-
clude van der Waals interaction, π–π bonding and ionic
interaction. Therefore, the results using this type of material
are hard to predict. Ribavirin, oseltamivir, amantadine,
rimantadine and arbidol are retained by the PBA cartridge
(Fig. 4b). Zanamivir and oseltamivir carboxylate do not
interact with the PBA material and elute during application
of the extract and the washing procedure. It stands out that
both compounds containing a carboxylic acid moiety are left
unretained by the PBA material. No explanation was found
for this observation.
From these results it is concluded that a combination of
SPE materials is needed to obtain a satisfactory clean-up for
all antiviral drugs included in this study. A tandem SPE
procedure was developed, a schematic of which is given in
Fig. 2a. All compounds except ribavirin were separated
from matrix constituents by retaining them on a Strata-X C
cartridge. The breakthrough of this cartridge, containing
ribavirin, was basified, centrifuged and applied onto a
PBA cartridge to retain ribavirin in order to separate this
drug from matrix constituents as well. Eventually, the elu-
ents of both cartridges were combined and the solvent was
evaporated. Finally, the residue was redissolved in 250 μL
of water. The matrix effects of the optimised clean-up pro-
cedure were determined using the C18 and the column-
switch system (Fig. 5a) and the recovery of the sample
preparation procedure (Fig. 5b) was determined.
From the comparison of Fig. 5a with Fig. 3, it is con-
cluded that the developed sample clean-up procedure
strongly contributes to the decrease of the matrix effect for
all compounds. The most striking is the decrease in the
suppression for zanamivir from 85% to 29%. After the
sample clean-up procedure, for arbidol, signal enhancement
(approximately 400%) is observed instead of signal suppres-
sion. From Fig. 5a it is concluded that applying the devel-
oped sample clean-up procedure in combination with RP
255Fig. 3 Matrix effects (signal
MMRS/signal standard) of the
antiviral drugs when using zic-
HILIC (light grey), C18 (medium
grey), Hypercarb (dark grey) and
the column-switch set-up
(black). 100% corresponds to no
matrix effects
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chromatography only is adequate for the analysis of ribavirin,
oseltamivir, oseltamivir carboxylate, rimantadine, amantadine
and arbidol, but the matrix effect for zanamivir is still very
pronounced and as a result 50 μg kg−1 of zanamivir in poultry
muscle is not detectable using solely RP chromatography.
Only when using the combination of the tandem SPE sample
clean-up procedure and the column-switch LC–MS/MS
system, the matrix effects are sufficiently decreased, enabling
detection and identification of all antiviral drugs included at
relevant levels. SRM chromatograms of a blank poultry mus-
cle sample spiked at 10 μg kg−1 with zanamivir and ribavirin
are presented in Fig. 6 and those of a blank poultry muscle
spiked at 2.5 μg kg−1 with the other antiviral drugs are
presented in Fig. 7.
a b
Fig. 4 Relative amount of antiviral drugs in the breakthrough during application of a 50 μg kg−1 spiked poultry muscle sample (light grey), the
breakthrough during washing (dark grey) and the elution (black) of (a) the Strata-X C and (b) the PBA SPE cartridge
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a b
Fig. 5 (a) Matrix effect (signal MMRS/signal standard) obtained for the antiviral drugs after the clean-up procedure when using RP C18 (light grey)
and the column-switch set-up (dark grey) as the chromatographic system (n05) and (b) the recovery of the sample clean-up procedure (n05)
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Column-switch set-up versus two individual injections
As an alternative to the use of the column-switch set-
up, the use of two individual injections on the RP and
the Hypercarb column was tested. This solely affects the
results for zanamivir and ribavirin, because the RP
system remains as it is in the column-switch system.
The matrix effects of zanamivir and ribavirin were eval-
uated after injection of a cleaned extract on the Hyper-
carb column and were both found to be 39%. It is
observed that the matrix effects for zanamivir using
injection on solely the Hypercarb column are increased
compared to the column-switch set-up. It is concluded
that additional matrix interferences are removed in the
first phase of the column switch set-up, which is ad-
vantageous for the analysis of zanamivir. For ribavirin
no statistically significant differences were observed and
thus it is concluded that the column-switch system is
advantageous in terms of the removal of matrix effects
and the analysis time (20 min instead of 40 min).
Therefore, the use of the column-switching system is
preferred.
Method validation
An overview of the validation results is presented in Table 2.
For zanamivir, ribavirin, oseltamivir, oseltamivir carboxyl-
ate, amantadine and rimantadine the linearity in the range of 0–
20 μg kg−1 is above the criterion of 0.990; the trueness is
between 95 and 108% for all antiviral drugs which is well
within the established criterion of 80–110%; the determined
maximum RSDr and RSDRL are 14.3% and 15.2%, respec-
tively, and thus below the criteria of 14.7% and 22%, respec-
tively; therefore, the validation results comply with the
established criteria. It is concluded that the presented method
is adequate for quantitative trace analysis of these six antiviral
drugs. For arbidol, inadequate linearity, trueness, repeatability
and within-laboratory reproducibility are observed. On two
validation days, the calibration lines are adequate, but on 1 day
the linearity is insufficient due to two deviating calibration
points. The poor trueness, repeatability and within-laboratory
reproducibility of arbidol are caused by 10 out of 63 spiked
samples showing a quantitative result that is 1.5–3.5 times
higher than expected. This is likely to be caused by a difference
in matrix interference, which plays a major role for arbidol
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Fig. 6 SRM chromatograms of
(a) blank poultry muscle sample
spiked with zanamivir and riba-
virin at 10 μg kg−1 including the
internal standards and (b) blank
poultry muscle sample spiked
with the internal standards only
Quantitative trace analysis of a broad range of antiviral drugs
(Fig. 5a). This effect might be overcome if a suitable internal
standard for arbidol becomes available. However, the pre-
sented method is suitable for the qualitative analysis of arbidol.
For oseltamivir, oseltamivir carboxylate, amantadine,
rimantadine and arbidol the calculated decision limits
(CCα) vary from 0.1 to 0.6 μg kg−1 indicating that for these
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Fig. 7 SRM chromatograms of
(a) blank poultry muscle sample
spiked with oseltamivir, oselta-
mivir carboxylate, rimantadine,
amantadine and arbidol at
2.5 μg kg−1 including the
internal standards and (b) blank
poultry muscle sample spiked
with the internal standards only
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antiviral drugs very low levels are still detectable. The calcu-
lated detection capabilities (CCβ) of these compounds are
between 0.5 and 2.5 μg kg−1 and samples spiked at
5 μg kg−1 were found to be non-compliant based upon the
ion ratio criteria [1] in 100% of the cases (n021), indicating
that the method is suitable for confirmatory analysis of these
antiviral drugs at relevant levels. For zanamivir and ribavirin
the calculated CCα values are 8 and 3 μg kg−1, respectively,
indicating that for these drugs relevant levels are still detect-
able. The calculated detection capabilities (CCβ) of zanamivir
and ribavirin are 15 and 9 μg kg−1, respectively. Even though
the calculated CCβ for zanamivir exceeds 10 μg kg−1, samples
spiked at 10 μg kg−1 with zanamivir and ribavirin were found
to be non-compliant based upon the ion ratio criteria [1] in
100% of the cases (n021) indicating that the calculated CCβ
for at least zanamivir is slightly overestimated and that the
method is suitable for confirmatory analysis of zanamivir and
ribavirin at relevant levels as well.
From the theoretical study hydroxyflunixin, ADD and
THG were found to have the same molecular mass as one
of the antiviral drugs and might theoretically interfere in the
described method. Standard solutions of 100 μg L−1 of these
compounds were prepared and injected into the column-
switch LC–MS/MS system. No interfering signals were
observed in these chromatograms and, furthermore, no sig-
nificant interferences were detected in the blank samples
(n021); therefore, the procedure is considered sufficiently
selective for the antiviral drugs.
During the method development some critical steps
were identified. Firstly the pH values of the solvents
used during the SPE clean-up procedure are critical.
The acidic methanol should be at pH≤2 to retain zana-
mivir on the Strata-X C material and the alkaline MeOH
should be at least pH 12 for the elution of amantadine
and rimantadine. Incorrect pH results in a severe decrease of
the recovery. Secondly, it was found critical to centrifuge the
basified breakthrough of the Strata-X C cartridge before
applying it onto the PBA cartridge to prevent clogging. For
ruggedness testing, three slight deviations to the procedure
that might occur in practice were specifically tested: (1)
extraction for 30 min instead of 15, (2) dry the PBA
cartridges by applying vacuum for 1 min after applying the
extract and after washing the cartridge and (3) evaporation of
the solvent at 55 °C instead of 50 °C. The duplicates analysed
by incorporating these deviations in the method showed good
trueness and acceptable duplicates, indicating that the tested
processes are robust.
Application to real samples
Two amantadine-affected muscle samples were analysed
using the developed method. The results were 4.9 μg kg−1
for the poultry muscle and 15.3 μg kg−1 for the turkey
muscle sample. These levels are in good agreement with
the indicated amantadine concentration, being approximately
4 μg kg−1 for the poultry muscle and 8–25 μg kg−1 for the
Table 2 Summary of the
validation study results Compound Validation level
(μg kg−1)
Trueness
(%)
RSDr
(%)
RSDRL
(%)
CCα
(μg kg−1)
CCβ
(μg kg−1)
Linearity (r2)
Zanamivir 5 95 11.3 15.2 8 15 0.990–0.996
10 101 11.4 15.0
15 107 11.1 11.6
Ribavirin 5 108 14.3 15.2 3 9 0.992–0.999
10 104 14.0 14.7
15 104 10.5 11.1
Oseltamivir 5 102 4.5 5.0 0.3 1.0 0.996–1.000
10 103 5.7 5.8
15 103 5.6 6.0
Oseltamivir
carboxylate
5 102 7.2 8.7 0.1 0.5 0.992–1.000
10 104 5.8 6.0
15 105 6.8 6.9
Amantadine 5 95 11.3 15.2 0.6 2.5 0.993–1.000
10 101 11.4 15.0
15 107 11.1 11.6
Rimantadine 5 101 3.2 3.4 0.1 0.5 0.998–1.000
10 101 3.7 3.9
15 102 4.4 4.5
Arbidol 5 118 34.6 39.0 0.3 1.0 0.974–1.000
10 129 39.2 55.7
15 130 61.8 64.7
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turkey muscle. From this it is concluded that the developed
method is applicable to real muscle samples.
Conclusions
A method using a tandem SPE sample preparation clean-up
combined with column-switch LC–MS/MS was developed
for the analysis of seven antiviral drugs in poultry muscle,
ranging from very polar to reasonably non-polar drugs, and
including basic, amphoteric and neutral compounds. The
removal of matrix interferences was critical for the detection
and quantification of zanamivir and ribavirin in particular.
Because neither compound was sufficiently retained by
using reversed-phase chromatography, a column-switch
LC system combining a reversed-phase and a Hypercarb
column was developed. This system showed improved sep-
aration power and is relatively easy to set-up, which is of
major importance in a routine situation. Furthermore, a
tandem SPE procedure proved to be mandatory for addi-
tional removal of matrix constituents. The method was fully
validated according to 2002/657/EC [1] at concentrations of
5, 10 and 15 μg kg−1. Good linearity, trueness, repeatability
and within-lab reproducibility were obtained for zanamivir,
ribavirin, oseltamivir, oseltamivir carboxylate, amantadine
and rimantadine. For arbidol these paramaters did not com-
ply with the established criteria because the method resulted
in a severe overestimation of the concentration for 16% of
the spiked samples. The selectivity and robustness proved to
be sufficient to apply the presented method in a routine
situation enabling parallel analysis of at least 48 samples
within 1 day. It is concluded that the presented method is
suitable for the quantitative confirmatory analysis of zana-
mivir and ribavirin at levels as low as 10 μg kg−1 and for
oseltamivir, oseltamivir carboxylate, amantadine and riman-
tadine at a concentration of 1 μg kg−1. Furthermore, the
presented method is suitable for the qualitative confirmatory
analysis of arbidol at a concentration of 1 μg kg−1.
Acknowledgements This project was financially supported by the
DutchMinistry of Economic Affairs, Agriculture and Innovation (project
1217261301). We thank Frédérique van Holthoon for her contribution to
the method development and FERA for kindly supplying amantadine-
affected muscle samples.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. EC (2002) Commission Decision 2002/657/EC of 12 August 2002
implementing Council Directive 96/23/EC concerning the perfor-
mance of analytical methods and the interpretation of results. Off J
Europ Commun L221:8–36
2. The Writing Committee of the World Health Organization (WHO)
Consultation on Human Influenza A/H5 (2005) Avian influenza A
(H5N1) infection in humans. N Engl J Med 353:1374–1385
3. WHO (2011) Avian influenza, fact sheet. WHO, Geneva
4. Malik Peiris JS, De Jong MD, Guan Y (2007) Avian influenza
virus (H5N1): a threat to human health. Clin Microbiol Rev
20:243–267
5. Mumford E, Bishop J, Hendrickx S, Embarek P, Perdue M (2007)
Avian influenza H5N1: risks at the human-animal interface. Food
Nutr Bull 28:S357–S363
6. Von Itzstein M (2007) The war against influenza: discovery and
development of sialidase inhibitors. Nat Rev Drug Discov 6:967–
974
7. He G, Qiao J, Dong C, He C, Zhao L, Tian Y (2008) Amantadine-
resistance among H5N1 avian influenza viruses isolated in North-
ern China. Antivir Res 77:72–76
8. Souza TML, Mesquita M, Resende P, Machado V, Gregianini TS,
Fernandes SB, Oliveira ICD, Rosa MdCD, Marinelli R, de
Azeredo-Lima CH, Motta FC, Aguiar-Oliveira MdL, Siqueira
MM (2011) Antiviral resistance surveillance for influenza A virus
in Brazil: investigation on 2009 pandemic influenza A (H1N1)
resistance to oseltamivir. Diag Microbiol Infect Dis 71:98–99
9. Zaraket H, Kondo H, Tabet C, Hanna-Wakim R, Suzuki Y, Dbaibo
GS, Saito R, Suzuki H (2011) Genetic diversity and antiviral drug
resistance of pandemic H1N1 2009 in Lebanon. J Clin Virol
51:170–174
10. Pawlotsky J-M (2011) Treatment failure and resistance with direct-
acting antiviral drugs against hepatitis C virus. Hepatology
53:1742–1751
11. Hayden FG, De Jong MD (2011) Emerging influenza antiviral
resistance threats. J Infect Dis 203:6–10
12. Thorlund K, Awad T, Boivin G, Thabane L (2011) Systematic
review of influenza resistance to the neuraminidase inhibitors.
BMC Infect Dis 11
13. Lyushina NA, Govorkova EA, Webster RG (2005) Detection of
amantadine-resistant variants among avian influenza viruses iso-
lated in North America and Asia. Virology 341:102–106
14. Weinstock DM, Zuccotti G (2006) Adamantane resistance in influ-
enza A. J Am Med Assoc 295:934–936
15. Ghosh GC, Nakada N, Yamashita N, Tanaka H (2010) Oseltamivir
carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu),
detected in sewage discharge and river water in Japan. Environ Health
Persp 118:103–107
16. Singer AC, Nunn MA, Gould EA, Johnson AC (2007) Potential
risks associated with the proposed widespread use of Tamiflu.
Environ Health Perspect 115:102–106
17. Fick J, Lindberg RH, Tysklind M, Haemig PD, Waldenström J,
Wallensten A, Olsen B (2007) Antiviral oseltamivir is not removed
or degraded in normal sewage water treatment: implications for
development of resistance by influenza A virus. PLoS One 2:e986
18. Cyranoski D (2005) China's chicken farmers under fire for anti-
viral abuse. Nature 435:1009
19. Delogu I, Pastorino B, Baronti C, Nougairède A, Bonnet E, de
Lamballerie X (2011) In vitro antiviral activity of arbidol against
Chikungunya virus and characteristics of a selected resistant mutant.
Antivir Res 90:99–107
20. FDA (2006) FDA prohibits use of antiviral drugs in poultry to help
keep drugs effective for humans. http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/2006/ucm108620.htm. Accessed
18 Jun 2009
21. Allen GD, Brookes ST, Barrow A, Dunn JA, Grosse CM (1999)
Liquid chromatographic-tandem mass spectrometric method for
the determination of the neuraminidase inhibitor zanamivir
(GG167) in human serum. J Chromatogr B 732:383–393
B.J.A. Berendsen et al.
22. Baughman TM, Wright WL, Hutton KA (2007) Determination of
zanamivir in rat and monkey plasma by positive ion hydrophilic
interaction chromatography (HILIC)/tandem mass spectrometry. J
Chromatogr B 852:505–511
23. Yeh LT, Nguyen M, Lourenco D, Lin CC (2005) A sensitive and
specific method for the determination of total ribavirin in monkey
liver by high-performance liquid chromatography with tandem
mass spectrometry. J Pharm Biomed Anal 38:34–40
24. Yeh LT, Nguyen M, Dadgostari S, Bu W, Lin CC (2007) LC-MS/
MS method for simultaneous determination of viramidine and
ribavirin levels in monkey red blood cells. J Pharm Biomed Anal
43:1057–1064
25. Liu Y, Xu C, Yan R, Lim C, Yeh LT, Lin CC (2006) Sensitive and
specific LC-MS/MS method for the simultaneous measurements of
viramidine and ribavirin in human plasma. J Chromatography B
832:17–23
26. Svensson JO, Bruchfeld A, Schvarcz R, Ståhle L (2000) Determi-
nation of ribavirin in serum using highly selective solid-phase
extraction and high-performance liquid chromatography. Ther
Drug Monit 22:215–218
27. Lindegårdh N, Hanpithakpong W, Wattanagoon Y, Singhasivanon
P, White NJ, Day NPJ (2007) Development and validation of a
liquid chromatographic-tandem mass spectrometric method for
determination of oseltamivir and its metabolite oseltamivir carbox-
ylate in plasma, saliva and urine. J Chromatogr B Anal Technol
Biomed Life Sci 859:74–83
28. Wiltshire B, Citron A, Clarke T, Serpe C, Gray D, Herron W (2000)
Development of a high-performance liquid chromatographic-mass
spectrometric assay for the specific and sensitive quantification of
Ro 64–0802, an anti-influenza drug, and its pro-drug, oseltamivir, in
human and animal plasma and urine. J Chromatogr B 745:373–388
29. Yamanaka T, Yamada M, Tsujimura K, Kondo T, Nagata S,
Hobo S, Kurosawa M, Matsumura T (2007) Clinical pharma-
cokinetics of oseltamivir and its active metabolite oseltamivir
carboxylate after oral administration in horses. J Vet Med Sci
69:293–296
30. Heinig K, Bucheli F (2008) Sensitive determination of oseltamivir
and oseltamivir carboxylate in plasma, urine, cerebrospinal fluid
and brain by liquid chromatography-tandem mass spectrometry. J
Chromatogr B 876:129–136
31. Bahrami G, Mohammadi B, Kiani A (2008) Determination of
oseltamivir carboxylic acid in human serum by solid phase extrac-
tion and high performance liquid chromatography with UV detec-
tion. J Chromatogr B 864:38–42
32. Ping W, Yi-Zeng L, Ben-Mei C, Neng Z, Lun-Zhao Y, Yan Y,
Zhi-Biao Y (2007) Quantitative determination of amantadine
in human plasma by liquid chromatography-mass spectrometry
and the application in a bioequivalence study. J Pharm
Biomed Anal 43:1519–1525
33. Xu M, Ju W, Xia X, Tan H, Chen M, Zhang J, Xiong N, Jiang M,
Chen L, Gong L (2008) Determination of rimantadine in rat
plasma by liquid chromatography/electrospray mass spectrometry
and its application in a pharmacokinetic study. J Chromatogr B
864:123–128
34. Feng S, Tian Y, Zhang Z, Zhang J, Huang M, Chen Y (2009)
Rapid simultaneous determination of paracetamol, amantadine
hydrochloride, caffeine and chlorpheniramine maleate in human
plasma by liquid chromatography/ tandem mass spectrometry.
Arzneim Forsch 59:86–95
35. Higashi Y, Uemori I, Fujii Y (2005) Simultaneous determination of
amantadine and rimantadine by HPLC in rat plasma with pre-
column derivatization and fluorescence detection for pharmacoki-
netic studies. Biomed Chromatogr 19:655–662
36. Shuangjin C, Fang F, Han L, Ming M (2007) New method for high-
performance liquid chromatographic determination of amantadine
and its analogues in rat plasma. J Pharm Biomed Anal 44:1100–1105
37. Liu X, Huang YW, Li J, Li XB, Bi KS, Chen XH (2007) Determi-
nation of arbidol in human plasma by LC-ESI-MS. J Pharm Biomed
Anal 43:371–375
38. Wang Y, Chen X, Li Q, Zhong D (2008) Metabolite identification
of arbidol in human urine by the study of CID fragmentation
pathways using HPLC coupled with ion trap mass spectrometry.
J Mass Spectrom 43:1099–1109
39. Chan D, Tarbin J, Sharman M, Carson M, Smith M, Smith S
(2011) Screening method for the analysis of antiviral drugs in
poultry tissues using zwitterionic hydrophilic interaction liquid
chromatography/tandem mass spectrometry. Anal Chim Acta
700:194–200
40. Horwitz W, Kamps LR, Boyer KW (1980) Quality assurance in the
analysis of foods and trace constituents. J Assoc Off Anal Chem
63:1344–1354
41. Thompson M, Ellison SL, Wood R (2006) The international harmo-
nized protocol for the proficiency testing of analytical chemistry
laboratories. Pure Appl Chem 78:145–196
42. Antignac J-P, Le Bizec BL, Monteau F, Andre F (2003) Validation
of analytical methods based on mass spectrometric detection
according to the “2002/657/EC” European decision: guideline
and application. Anal Chim Acta 483:325–334
Quantitative trace analysis of a broad range of antiviral drugs
